Laboratory Corp (LH) Receives a Buy from Morgan Stanley


In a report released today, Ricky Goldwasser from Morgan Stanley maintained a Buy rating on Laboratory Corp (LH), with a price target of $201. The company’s shares closed last Monday at $167.94.

According to TipRanks.com, Goldwasser is a 4-star analyst with an average return of 4.3% and a 56.5% success rate. Goldwasser covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Quest Diagnostics Inc, and Molina Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Laboratory Corp with a $187.14 average price target, which is an 11.4% upside from current levels. In a report issued on August 8, KeyBanc also maintained a Buy rating on the stock with a $192 price target.

See today’s analyst top recommended stocks >>

Laboratory Corp’s market cap is currently $16.41B and has a P/E ratio of 19.87. The company has a Price to Book ratio of 2.30.

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts